MM patients undergoing CAR-T therapy targeting MM surface antigens, such as CD138 and CD229, may experience blocking of these antigen-binding sites for several months [39], This necessitates adjustments in the use of NGF for MRD detection. This evidence concerns the gene NGF and Miyoshi myopathy.